Methylation changes in the 9p21 chromosomal regions consisting of the cyclin-dependent kinase inhibitor 2B (CDKN2B) and cyclin-dependent kinase inhibitor 2A (CDKN2A) genes have been frequently associated with myelodysplastic syndromes and AML. This evidence concerns the gene CDKN2A and acute myeloid leukemia.